Author:
Nam Bora,Choi Nayeon,Koo Bon San,Kim Jiyeong,Kim Tae-Hwan
Funder
Ministry of Health & Welfare, Republic of Korea
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379–90.
2. Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19–34.
3. Anghel L-A, Farcaş AM, Oprean RN. Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review. Patient Prefer Adherence 2018:1151–66.
4. Biggioggero M, Favalli EG. Ten-year drug survival of anti‐TNF agents in the treatment of inflammatory arthritides. Drug Dev Res. 2014;75:S38–41.
5. Scirè C, Caporali R, Puttini S, Frediani P, Di Franco B, Tincani M. Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database. Clin Exp Rheumatol. 2013;31(6):857–63.